Avastin may lose significant patient share to Sanofi-Aventis' BSI-201, according to r
 

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that an overall survival benefit would be the most influential factor for three-quarters of surveyed European oncologists in their decision to prescribe a novel agent ahead of Avastin for the treatment of breast cancer.

More...

Re: Avastin may lose significant patient share to Sanofi-Aventis' BSI-201, according
 

Until there's a cure, let's celebrate each dethroning of the previous best in class.